Drug pharmacy – Prices Vardenafil Levitra http://pricesvardenafillevitra.com/ Thu, 30 Jun 2022 17:11:13 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://pricesvardenafillevitra.com/wp-content/uploads/2021/10/icon-26.png Drug pharmacy – Prices Vardenafil Levitra http://pricesvardenafillevitra.com/ 32 32 27-year-old man charged after robbery in Whitby, Ont., pharmacy: police https://pricesvardenafillevitra.com/27-year-old-man-charged-after-robbery-in-whitby-ont-pharmacy-police/ Thu, 30 Jun 2022 16:47:01 +0000 https://pricesvardenafillevitra.com/27-year-old-man-charged-after-robbery-in-whitby-ont-pharmacy-police/ A 27-year-old man has been charged with robbery at a Whitby pharmacy, police say. Durham Regional Police said on May 30 at around 8pm officers received a report of a robbery at a Shoppers Drug Mart on Garden Street and Rossland Road. Police said the suspect entered the store and grabbed a cell phone from […]]]>

A 27-year-old man has been charged with robbery at a Whitby pharmacy, police say.

Durham Regional Police said on May 30 at around 8pm officers received a report of a robbery at a Shoppers Drug Mart on Garden Street and Rossland Road.

Police said the suspect entered the store and grabbed a cell phone from the counter.

Officers allege the man then left the store without paying.

Read more:

Police are looking for witnesses after a hit-and-run in Whitby, Ont.

According to the police, the man was confronted by an employee.

According to the police, the suspect then brandished a knife and threatened to kill the employee.

The story continues under the ad

“It is believed he left on a dark mountain bike,” police said in a news release.

Police have arrested 27-year-old Corey Voskamp.

He was charged with robbery, possession of a dangerous weapon and carrying a concealed weapon.

Anyone with information is asked to contact the police or Crime Stoppers.

© 2022 Global News, a division of Corus Entertainment Inc.

]]>
Pharmacy sees emergency contraceptive sales jump 3,000% after Roe ruling https://pricesvardenafillevitra.com/pharmacy-sees-emergency-contraceptive-sales-jump-3000-after-roe-ruling/ Tue, 28 Jun 2022 19:25:00 +0000 https://pricesvardenafillevitra.com/pharmacy-sees-emergency-contraceptive-sales-jump-3000-after-roe-ruling/ Women across the United States are stocking up on emergency contraceptives after the Supreme Court overturned its landmark ruling protecting a woman’s right to an abortion. Online reproductive and sexual health provider Wisp, which sells two different types of so-called morning-after pills, said it witnessed an unprecedented 3,000% increase in sales of emergency contraceptives after […]]]>

Women across the United States are stocking up on emergency contraceptives after the Supreme Court overturned its landmark ruling protecting a woman’s right to an abortion.

Online reproductive and sexual health provider Wisp, which sells two different types of so-called morning-after pills, said it witnessed an unprecedented 3,000% increase in sales of emergency contraceptives after the decision to the Supreme Court on Friday quash Roe v. Wade.

Sales of morning-after pills have continued to rise every day since and so far the company has been able to meet demand, Wisp CEO Ahmad Bani said in a statement to CBS MoneyWatch.

Customers first flocked to the Wisp website in May after a high court draft the decision on Roe has been leaked. At the time, Wisp saw a 40% increase in sales of emergency contraception products and services over the previous month, Bani said.


Next steps now that Roe v. Wade was canceled

09:43

Wisp sells Levonorgestrel, a generic version of the Plan B pill, for $17. The pills can be taken within three days of unprotected sex or contraceptive failure. Wisp also sells another type of emergency contraceptive called Ella, which can be taken within five days of having sex, costs $22 and requires a prescription.

Some retailers, including national drugstore chains CVS and Rite Aid, ration drugs to preserve supply in the face of soaring demand.

CVS said Monday it was temporarily limiting purchases of morning-after pills to three boxes per transaction after seeing a surge in the sale of emergency contraceptives immediately after the Supreme Court ruling.

In a statement, the pharmacy chain said it had an “adequate supply” of Plan B and Aftera, another branded product that women can take to prevent pregnancy after unprotected sex or in case of failure of a method of contraception. By Tuesday, sales had stabilized, according to a spokesperson, who said CVS was “removing purchase limits, which will take effect in stores and on CVS.com over the next 24 hours.”

Emergency contraceptives generally work by delaying or preventing ovulation and are intended as a back-up method of birth control. Medications are distinct from abortive medications, which terminate pregnancies. Plan B costs $49.99 for a single pill, while Aftera costs $39.99.

Rite Aid is also limiting purchases of emergency contraceptives, including Plan B and Option 2 brand pills. Customers are limited to three pills per order, a spokesperson for the drugstore chain told CBS MoneyWatch.

]]>
Internet Pharmacy Rules: Clear Regulatory Guidance Needed https://pricesvardenafillevitra.com/internet-pharmacy-rules-clear-regulatory-guidance-needed/ Sat, 25 Jun 2022 18:07:41 +0000 https://pricesvardenafillevitra.com/internet-pharmacy-rules-clear-regulatory-guidance-needed/ Concerned about the excessive delay in finalizing rules and regulations for the nascent online pharmacy sector to control the online sale of medicines in the country, the Parliamentary Standing Committee of the Ministry of Commerce has recommended to the central government that the draft of e-pharmacy rules which the Union Health Ministry issued almost four […]]]>

Concerned about the excessive delay in finalizing rules and regulations for the nascent online pharmacy sector to control the online sale of medicines in the country, the Parliamentary Standing Committee of the Ministry of Commerce has recommended to the central government that the draft of e-pharmacy rules which the Union Health Ministry issued almost four years ago should be finalized and implemented at the earliest.

The parliamentary committee, in its report on “Promotion and Regulation of E-Commerce in India”, which was presented to the President of Rajya Sabha on June 15, said that a comprehensive guideline for pharmacy or health platforms online should be released by the government without further delay.

Appalled that the draft e-pharmacy rules have yet to be finalized years after a high-level committee was formed for the purpose, the parliamentary committee, chaired by MP V Vijayasai Reddy, reiterated this undue delay in the adoption of a final regulation. regulatory framework will lead to uncertainty that is not conducive to rapidly evolving digital markets.

The Committee, while appreciating the rise of electronic commerce in the pharmaceutical and health sector, expressed concern about the possible misuse of these channels for the distribution of illegal or unethical drugs or of expired, substitute or counterfeit medicines in the absence of regulation. Strict regulation of the e-health and e-pharmacy sector is essential given the potential damage it can cause to the health of the end user if abused.

It is evident that the scope of e-commerce in the pharmaceutical industry is immense and if properly regulated, online pharmacies in India could prove beneficial to various stakeholders. However, there is a serious need to frame the laws in India as the online pharmacy laws in India are still in their infancy and there are no dedicated online pharmacy laws in India.

It is clear that in the absence of regulatory guidelines, there is always a threat and possibility of supplying illegal or unethical drugs or expired, substitute or counterfeit drugs to the person who ordered the drug at the instead of real medicine. There are also other concerns, including the potential lack of confidentiality, improper packaging, and consumption of harmful drug interactions, among several other issues.

In such a context, a comprehensive guideline that encompasses due diligence measures should be undertaken by online pharmacy platforms; mandatory registration with the competent authority for the sale of drugs should be done, the assignment of responsibility on these platforms for the sale of genuine drugs, the regulation of the sale of controlled drugs, etc. should be formulated in consultation with all stakeholders.

It is now abundantly clear that the national online pharmacy market is brimming with activity with the entry of billionaires like Jeff Bezos and Mukesh Ambani into the nascent sector. And according to available data, the Indian e-pharmacy market, with around 50 e-pharmacies and accounting for 14% of the total e-pharmacy revenue in the Asia-Pacific region in 2020, is expected to grow at a CAGR higher. by around 40-45% compared to global e-pharmacy markets which are expected to grow at a CAGR of around 15-20%.

Furthermore, drug expenditure in India is expected to increase by 9-12% over the next five years. But unfortunately, the country does not currently have a regulatory mechanism for the online sale of drugs and the laws governing the physical pharmacy sector also apply to online pharmacies. The Drugs and Cosmetics Act (D&C Act) does not distinguish between the conventional sale and the online sale of drugs.

Pursuant to Section 18(c) of the D&C Act of 1940 to be read with Rule 65, only a licensed retailer is permitted to sell drugs and that too on the basis of a doctor’s prescription only. Rule 65 stipulates the sale of drugs under the supervision of a licensed pharmacist, which also involves the signature of the invoice and the stamp of the prescription by the pharmacist and the doctor.

But, according to reports, as the existing laws are vague on the matter, there is a rampant sale of prescription drugs by online pharmacies in violation of the country’s existing laws. In the current circumstances of the Covid-19 pandemic, when the government and the medical fraternity have asked people to stay indoors, the relevance of online pharmacy is much greater.

But, in the absence of clear provisions in the D&C Act regarding the sale of drugs through online pharmacies, complete confusion reigns in the country’s pharmaceutical market, which has resulted in a verbal duel between the associations of offline pharmacies and on line. This scenario should end. The government should waste no more time finalizing proprietary rules for the nascent online pharmacy industry in India.

(The author is a freelance journalist with a varied background

in different domains)

]]>
Amber Specialty Pharmacy Announces Expansion of EVUSHELD™ Services https://pricesvardenafillevitra.com/amber-specialty-pharmacy-announces-expansion-of-evusheld-services/ Thu, 23 Jun 2022 14:12:00 +0000 https://pricesvardenafillevitra.com/amber-specialty-pharmacy-announces-expansion-of-evusheld-services/ OMAHA, Neb.–(BUSINESS WIRE)–Amber Specialty Pharmacy announces the launch of EVUSHELD™ extended services. The United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for AstraZeneca’s EVUSHELD™ (tixagevimab co-packaged with cilgavimab) for pre-exposure prophylaxis of coronavirus 2019 (COVID-19) in adults and children (12 years and older weighing at least 40 kg). EVUSHELD™ […]]]>

OMAHA, Neb.–(BUSINESS WIRE)–Amber Specialty Pharmacy announces the launch of EVUSHELD™ extended services. The United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for AstraZeneca’s EVUSHELD™ (tixagevimab co-packaged with cilgavimab) for pre-exposure prophylaxis of coronavirus 2019 (COVID-19) in adults and children (12 years and older weighing at least 40 kg).

EVUSHELD™ can be prescribed to people who are not currently infected with SARS-CoV-2 and have not recently been exposed to someone infected with SARS-CoV-2 and

  • Who have a moderate to severe immune deficiency due to a medical condition or receiving immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination Where

  • For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of serious adverse reaction to one or more COVID-19 vaccines and/or to one or more components of the COVID-19 vaccine.

This may include transplant recipients, as well as oncology and other immunocompromised patients. Amber Specialty Pharmacy’s high-level contact service model is designed to support prescribers, such as transplant programs, oncologists and others, who may have patients who may be prescribed EVUSHELD™. The pharmacy provides comprehensive services from the time of referral through delivery and beyond to ensure the best possible patient outcomes.

Amber Specialty Pharmacy will offer EVUSHELD™ at its 19 locations across the United States. They can also coordinate delivery and nursing care for home administration, if necessary.

“Throughout the pandemic, Amber Specialty Pharmacy has always embraced the opportunity to care for our patients. Through the administration of monoclonal antibodies, we focused on providing solutions when our patients needed them most,” said Kristin Williams, President of Amber Specialty Pharmacy. “Our expanded EVUSHELD™ services represent our continued commitment to caring for our patients, especially those who have not had treatment options that provide an adequate immune response.”

For more information about Amber Specialty Pharmacy services, call (888) 370-1724 or visit www.amberpharmacy.com. Learn more about the pharmacy’s COVID-19 therapy offerings here.

Amber Specialty Pharmacy, a subsidiary of Hy-Vee, Inc., is a pioneer and leader in the specialty pharmacy industry with nearly 25 years of experience providing specialty care to people with complex chronic conditions. Amber Specialty Pharmacy has built an exceptional reputation for providing personalized support and quality clinical care to patients and families. This comprehensive care approach meets the medical, emotional, financial and administrative needs of patients across the United States. Amber Specialty Pharmacy is accredited by the Use Review Accreditation Commission (URAC) and the Healthcare Accreditation Commission (ACHC). Amber Specialty Pharmacy is headquartered in Omaha, Nebraska, with 18 additional locations in the United States and Puerto Rico. Amber Specialty Pharmacy has been named the 2020 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacies.

]]>
Skippack Pharmacy takes unique approach to vaccinating children 6 months to 5 years against COVID-19 – CBS Philly https://pricesvardenafillevitra.com/skippack-pharmacy-takes-unique-approach-to-vaccinating-children-6-months-to-5-years-against-covid-19-cbs-philly/ Wed, 22 Jun 2022 02:03:00 +0000 https://pricesvardenafillevitra.com/skippack-pharmacy-takes-unique-approach-to-vaccinating-children-6-months-to-5-years-against-covid-19-cbs-philly/ SCHWENKSVILLE, Pa. (CBS) — Another milestone in the pandemic response. Health workers began administering COVID-19 vaccines to children aged 6 months to 5 years on Tuesday. At a local pharmacy, a doctor takes a rather unique approach when it comes to vaccinating this age group. Parents came from all over to have their children vaccinated […]]]>
]]>
Walmart to hire 5,000 pharmacy technicians and raise salaries https://pricesvardenafillevitra.com/walmart-to-hire-5000-pharmacy-technicians-and-raise-salaries/ Mon, 20 Jun 2022 21:02:05 +0000 https://pricesvardenafillevitra.com/walmart-to-hire-5000-pharmacy-technicians-and-raise-salaries/ Walmart announced initiatives to celebrate the company’s pharmacy technicians, including pay raises and hiring more technicians this year. Calling pharmacy technicians “heroes,” Walmart announced that the company is raising salaries for its more than 36,000 Walmart and Sam’s Club pharmacy technicians and plans to hire about 5,000 more technicians this year. “Our Walmart and Sam’s […]]]>

Walmart announced initiatives to celebrate the company’s pharmacy technicians, including pay raises and hiring more technicians this year.

Calling pharmacy technicians “heroes,” Walmart announced that the company is raising salaries for its more than 36,000 Walmart and Sam’s Club pharmacy technicians and plans to hire about 5,000 more technicians this year.

“Our Walmart and Sam’s Club Pharmacy Technicians have proven time and again how much they mean to the communities they serve. They were front and center during the pandemic as we tested millions of customers and members, and many went above and beyond to help administer vaccines across the country,” wrote Kevin Host, senior vice president of Walmart. Health & Wellness, Pharmacy and Sean Jackson, Sam’s Club GMM Senior Vice President, Health & Wellness/Consumables, in an article on Walmart.com.1

“These associates provided moments of heartfelt care in extraordinary circumstances, and they did so with a smile and the calm, professional attention that builds trust and keeps patients coming back,” Host and Jackson continued. “Simply put, our pharmacy technicians are heroes in their communities. They also play an essential day-to-day role in the continued growth of our Health and Wellbeing business.

For the second time in the past year, Walmart is making “significant investments in higher salaries and career progression for our pharmacy technicians, with the goal of creating additional growth paths and opportunities for them,” Host and Jackson said.

Effective the week of June 13, Walmart and Sam’s Club are raising the average hourly wage for pharmacy technicians to more than $20 an hour, following a wage increase last August.

“It’s by design. We send a strong signal to pharmacy technicians everywhere that Walmart is committed to attracting top talent and giving them the tools they need to build successful careers,” Host and Jackson said.

The 2 retail chains will also give technicians more frequent automatic pay raises, “as we introduce a new progressive pay model designed to set us apart from the competition,” Host and Jackson said.

For example, new Pharmacy Technicians will receive raises that can add up to $4 to their starting base salary over a 4-year period. Additionally, Technicians will receive raises every 6 months during their first 2 years with the company.

“We believe we are among the first major retailers to incorporate this type of model, an approach commonly seen in healthcare systems. This will help associates increase their pay faster as they build their careers and continue to work at Walmart,” Host and Jackson said.

Sam’s Club and Walmart also plan to hire an additional 5,000 technicians this year, “to support our vision to provide best-in-class healthcare,” Host and Jackson wrote. “Our business is growing and we will continue to invest in our entire Health and Wellness team to help drive that growth.”

In addition to the raises, retailers will pay for eligible associates to become certified pharmacy technicians through benefits like Live Better U and related programs.

“Walmart Certified Technicians can earn $3 more per hour than their uncertified peers, which means earning certification can make a big difference for associates and their families,” Host and Jackson wrote. “To remove any barriers, Walmart is covering the costs of earning Pharmacy Technician Certification – from career credentials, on-the-job training, and test preparation, to paying the pharmacy technician exam fee. certificate.”

Reference

1. Host, K., Jackson, S. Walmart launches new approach to pharmacy technician salaries with more frequent raises. Walmart.com. Published June 16, 2022. Accessed June 17, 2022. https://corporate.walmart.com/newsroom/2022/06/16/walmart-launches-new-approach-to-pharmacy-tech-wages-with-more- frequent reminders

]]>
With a focus on generic drugs, online pharmacy startup Truemeds is helping cut drug bills by 47% https://pricesvardenafillevitra.com/with-a-focus-on-generic-drugs-online-pharmacy-startup-truemeds-is-helping-cut-drug-bills-by-47/ Sun, 19 Jun 2022 01:46:00 +0000 https://pricesvardenafillevitra.com/with-a-focus-on-generic-drugs-online-pharmacy-startup-truemeds-is-helping-cut-drug-bills-by-47/ Healthcare costs have risen dramatically in recent years, owing to India’s growing population, aging elderly, incidence of diseases, utilization of medical services, rising drug costs and other factors. Across the country, people who must take medication on a daily basis largely spend out of pocket and end up shelling out large sums over the years. […]]]>

Healthcare costs have risen dramatically in recent years, owing to India’s growing population, aging elderly, incidence of diseases, utilization of medical services, rising drug costs and other factors.

Across the country, people who must take medication on a daily basis largely spend out of pocket and end up shelling out large sums over the years.

Mumbai-based health tech start-up Truemeds aims to help change that by lowering the price of drug bills “as much as possible”. 47 percent” by offering alternative medicines.

The Mumbai-based online pharmacy was founded in 2019 by Akshat Nayyar and Dr Kunal Wani, who previously worked for a pharmaceutical company. The duo were intrigued by the prospect of generic drugs and how they could help patients lower their drug bills.

Truemeds claims to reduce pharmacy bills by 47%

According to the US FDA, a generic drug is a drug created to be identical to an already marketed brand name drug in terms of dosage form, safety, strength, route of administration, quality, performance characteristics, and drug use. intended use.

These similarities help demonstrate bioequivalence, which means that a generic drug works the same way and provides the same clinical benefit as the brand name drug.

Throughout the world, the pharmaceutical market is made up of players holding original patents and players working on (generic) patents. According to industry estimates, approximately 95 percent drugs available on the Indian market are off-patent.

Brand name drugs are more expensive as companies undertake significant sales and marketing activities for these drugs. Marketed generics, on the other hand, offer the same efficacy but at a lower cost.

The founders of Truemeds saw an opportunity in bringing these low-cost drugs to chronic patients.

“We wanted to address the issue of drug affordability so that patients could have them as a right rather than a privilege,” Akshat says.

The founders spent time researching this industry and realized they could harness the technology to reduce regular medical bills. They received an initial investment from the managing director of Abbot India, the company they both worked at, and got started.

How the model works

On Truemeds, a patient needs to upload the prescription to the site. The startup has built algorithms that analyze more than two lakh drugs and suggest accurate alternatives that are priced lower.

The online pharmacy also has a panel of doctors to answer any doubts that patients may have when ordering these generic drugs because they are not the ones prescribed by their doctor. Only after all this are the drugs sold and delivered.

“Patients are generally unaware of available alternatives and we only suggest quality drugs with the same levels of efficacy,” says Akshat.

Truemeds started out as an alternative medicine recommendation business, but the team later realized that consumers needed to be accompanied through the process, even after delivery.

Akshat says that on average, Truemeds is able to deliver savings of 47 percent for clients if they switch brands of drugs. If they decide not to go for the generic drug, it provides drugs at a standard price 20 percent delivery.

The startup is able to offer savings due to two factors: marketed generic drugs are available at a lower price, and the company absorbs the margin costs of sales and marketing (so they are not passed on to the consumer).

The pharmaceutical industry is quite complex, with a mixture of relationships between manufacturers, resellers or distributors and doctors.

Truemeds works with over 150 distributors

Truemeds, which now has a 100 member teamworks with pharmaceutical companies and distributors to source medicines.

Akshat says, “We work with over 150 distributors and there is no reason to bypass them as they add value to the entire supply chain.

Truemeds has partnerships with several logistics companies like Delhivery, Blue Dart, Xpressbees, etc.

Growth and purpose

Truemeds began operations in Bombay, and in a short time covered the state of Maharashtra. It has now spread to other cities like Delhi, Kolkata and Bangalore where he set up distribution centers. The startup has plans to cover more locations.

COVID-19 brought some tailwinds to the Truemeds business as consumers spent more time online and also looked for ways to save money, given the impact of the pandemic on the means of subsistence.

“As of April 2020, we have been cultivating 78X and supplying drugs nationwide,” Akshat says. The startup serves 18,000 PIN codes Across the country.

Truemeds claims to deliver around a lakh of orders per month, and says it is growing on average by 20% month after month. The goal is to bring it to five lakh orders by March 2023.

The startup raised approx. $27 million in funding to date from investors such as WestBridge Capital, InfoEdge Ventures, Indian Angel Network Fund, etc.

Market and outlook

The pharmaceutical market in India is $25 billion in size, according to Akshat, and he thinks Truemeds just scratched the surface.

Citing statistics, he says the share of generic prescription drugs in the United States has increased from 40% in 2005 to 86%. In India, the share is only 8% and is expected to reach 45% by 2025.

“We would like to be the leader in the field of marketed generics, with an emphasis on patient well-being,” says Akshat.

Competition for Truemeds comes from other health tech startups like Medcard, Stay Happy and Dawaa Dost, but the co-founder thinks it’s best to have more players because the need of the hour is “d ‘evangelizing alternative medicines or marketed generics’.

The main challenge is that patients do not easily turn to cheaper generic drugs, which makes awareness raising vital.

“Our goal is to meet customer expectations and provide them with a good overall experience,” says Akshat.

Edited by Teja Lele Desai
]]>
EPIQ Scripts, a subsidiary of the AMIH, obtains a pharmacy license with https://pricesvardenafillevitra.com/epiq-scripts-a-subsidiary-of-the-amih-obtains-a-pharmacy-license-with/ Thu, 16 Jun 2022 13:00:00 +0000 https://pricesvardenafillevitra.com/epiq-scripts-a-subsidiary-of-the-amih-obtains-a-pharmacy-license-with/ Dallas, Texas, June 16, 2022 (GLOBE NEWSWIRE) — American International Holdings Corp. (OTCQB: AMIH) (“AMIH” or the “Company”), a diversified holding company that develops, acquires and operates health and wellness technology companies, is pleased to announce that its subsidiary, EPIQ Scripts, LLC (“EPIQ Scripts”), received a pharmacy license from the Texas State Board of Pharmacy […]]]>

Dallas, Texas, June 16, 2022 (GLOBE NEWSWIRE) — American International Holdings Corp. (OTCQB: AMIH) (“AMIH” or the “Company”), a diversified holding company that develops, acquires and operates health and wellness technology companies, is pleased to announce that its subsidiary, EPIQ Scripts, LLC (“EPIQ Scripts”), received a pharmacy license from the Texas State Board of Pharmacy (“TSBP”).

In addition to obtaining a pharmacy license from the TSBP, EPIQ Scripts has also obtained its National Provider Identification Number (NPI) and is now a member of the National Council of Prescription Drug Programs (NCPDP), an organization of development of standards.

EPIQ Scripts plans to operate as an online mail-order pharmacy, with the specific objective of serving and supporting telehealth and telemedicine companies, and their respective customers and patients, who have rapidly entered the market.

According to a July 2021 report by All The Research, the global online pharmacy market was valued at $68.2 billion in 2020, and it is expected to reach $202.3 billion by 2027, a rate of compound annual growth (CAGR) of 16.8%. All The Research expects the growth of the online pharmacy market to be attributed to an increase in the number of internet consumers, increased access to online services, increased government support with favorable policies and the increasing fulfillment of electronic prescriptions in healthcare facilities.

“I am extremely pleased with the significant achievements and progress made by EPIQ Scripts in such a short time, since its official launch in early February,” commented Jacob Cohen, President and CEO of AMIH, who continued “In just over three months, EPIQ Scripts has (i) assembled a fully equipped, staffed and operational pharmacy occupying approximately 3,000 square feet, (ii) submitted its application to the Utilization Review Accreditation Commission (URAC ), (iii) obtained their pharmacy license from the Texas State Board of Pharmacy, (iv) become a member of the NCPDP, and (v) receive their National Provider Identification Number (NPI). EPIQ Scripts to focus on its business development and to continue its expansion initiatives in other states of the United States.

“With our initial Texas State Board of Pharmacy license now in place, EPIQ Scripts will now focus on securing pharmacy licenses and accreditations in the remaining 49 states of the United States, so that we can attract and support businesses telemedicine companies seeking to reach customers nationwide,” commented Sultan Haroon, Director and COO of EPIQ Scripts. “Our goal is to eventually position EPIQ Scripts to compete with TruePill – the online pharmacy that provides fulfillment services to popular telemedicine companies such as Hims and Hers and GoodRx and was recently valued by TruePill at $1.6 billion. dollars – and other online digital pharmacies that we are looking for to rapidly deploy our solutions in important telemedicine markets,” Mr. Haroon added.

About American International Holdings Corp.
American International Holdings Corp. (OTCQB: AMIH) is an investor, developer and asset manager of diversified and synergistic health and wellness businesses. Today, AMIH’s portfolio includes telemedicine and other virtual health platforms, affordable subscription-based primary care and concierge medicine plans, preventative care solutions, and wellness-related assets such as as mental and behavioral health services, as well as its own proprietary life coaching platform. AMIH markets its various services through direct-to-consumer and business-to-business distribution channels. AMIH is focused on bringing to market technologies and solutions that improve the quality of life of the global community.

Forward-looking statements
This press release may contain forward-looking statements, including information about management’s view of the Company’s future expectations, plans and prospects, within the meaning of federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may also be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans regarding our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as ‘anticipate’, ‘intend’, ‘plan’, ‘aim’, ‘seek’, ‘believe’, ‘project’, ‘estimate’, ‘s ‘expect’, ‘strategy’, ‘future’, ‘likely’, ‘could’, ‘should’, ‘should’, ‘could’, ‘should’ and other words of similar meaning in discussion on future operational or financial performance. Examples of forward-looking statements include, but are not limited to, statements relating to future sales, operations, expansion, earnings, cash flow, results of operations, uses of cash and other measures. financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the actual results and financial condition of the Company to differ materially from those expressed or implied by forward-looking statements. These risks, uncertainties and other factors include, among others, such as, but not limited to, the proposed operations of EPIQ Scripts, the ability of EPIQ Scripts to obtain the required licenses and accreditations, the timing of such licenses and accreditations, and limitations on its operations if such licenses and accreditations are not in place, and forecasts of future revenues, customers and operating results of EPIQ Scripts; economic conditions, changes in laws or regulations, demand for the Company’s products and services; our limited operating history; our need for additional financing to support our operations, repay debt and expand our operations; the effects of COVID-19 on our operations and prospects, and the future effects of COVID-19 on us and our operations; impairments that we may need to assess in relation to our assets and our goodwill; risks associated with our prior launch of a telehealth platform, including related liability, funding required to support such operations and other risks associated with the operations of the telehealth platform; disruptions to our operations or liabilities associated with future acquisitions; our ability to continue as a going concern; our dependence on our Chief Executive Officer, Jacob D. Cohen, and related party transactions affecting the Company; control of Mr. Cohen’s voting rights in the Company; the competition we face; our ability to maintain our varied operations and service our indebtedness; material weaknesses in our controls and procedures; our ability to obtain and maintain adequate insurance; legal challenges and litigation; risks associated with national and global recessions and inflation; liability associated with our contractual operations; the terms of Mr. Cohen’s employment contract; dilution caused by the conversion of outstanding notes, the exercise of outstanding warrants and future fundraising activities; the anti-dilution and favored nation provisions of our outstanding convertible notes and warrants; the price, volatility and lack of a robust trading market for our common stock; compliance with listing standards and the Company’s ability to list on NASDAQ; and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. These and other risk factors are included from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections of its forms. 10-K and 10-Q and in its Form 8-K, which it has filed and files from time to time with the United States Securities and Exchange Commission. These reports are available at www.sec.gov. The forward-looking statements included in this press release speak only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to publicly update these forward-looking statements to reflect actual results, new information or future events, changes in assumptions, or changes in other factors affecting the forward-looking statements, except to the extent required. by applicable laws. If we update one or more forward-looking statements, no conclusion should be drawn that we will make additional updates with respect to such or other forward-looking statements.

Investor Relations
Frank Benedetto
(619) 915-9422

]]>
Pharmacy Automation Market Size, Industry to Witness Exceptional Growth During 2022-Industry-2029 – Designer Women https://pricesvardenafillevitra.com/pharmacy-automation-market-size-industry-to-witness-exceptional-growth-during-2022-industry-2029-designer-women/ Mon, 13 Jun 2022 11:32:05 +0000 https://pricesvardenafillevitra.com/pharmacy-automation-market-size-industry-to-witness-exceptional-growth-during-2022-industry-2029-designer-women/ Data Bridge Market Research analyzes that the pharmacy automation market was valued at USD 5.07 billion in 2021 and is further projected to reach USD 9.88 billion by 2029, and is expected to grow at a CAGR of 8.7% during the forecast period from 2022 to 2029. Automated medication dispensing systems accounted for the largest […]]]>

Data Bridge Market Research analyzes that the pharmacy automation market was valued at USD 5.07 billion in 2021 and is further projected to reach USD 9.88 billion by 2029, and is expected to grow at a CAGR of 8.7% during the forecast period from 2022 to 2029. Automated medication dispensing systems accounted for the largest share of the pharmacy automation market due to benefits such as better medication safety, better inventory management, and increased storage capacity with optimal utilization of the drug. space, as well as potential savings in time and money.

Pharmacy Automation Industry Market ReportThis helps to focus on important aspects of the market such as recent market trends and market conditions. The Pharmaceutical Automation Industry market report has been structured after an in-depth study of various key market segments such as market size, share, growth, demand, latest trends, market threats, and key drivers driving the market. Moreover, the report also contains all the information, including market definition, classifications, key developments, applications and commitments, while detailing the actions of major players with respect to product launches, joint ventures , developments, mergers and acquisitions and their effects in terms of sales, import, export, revenue and CAGR values. This industry analysis report talks about the manufacturing process, type and applications in detail. The compelling Pharmacy Automation Industry report consists of drivers and restraints for the market which are obtained using SWOT analysis along with their impact on the demand over the forecast period.

Get the Sample PDF Copy (Including Full TOC, Graphs and Tables) of this Report@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacy-automation-market&Ab

Some of the major players operating in the pharmacy automation market are:

Talyst, LLC. (WE)

ARxIUM (USA)

OMNICELL, INC. (UNITED STATES)

Cerner Corporation (USA)

Capsa Healthcare (USA)

Parata Systems, LLC (USA)

RxSafe, LLC. (WE)

RxMedic Systems, Inc. (USA)

MedAvail Technologies, Inc. (Canada)

Asteres Inc. (USA)

PerceptiMed, Inc. (USA)

comics (US)

Baxter (USA)

Fulscript (Canada)

McKesson Corporation (USA)

AmerisourceBergen Corporation (USA)

vitabook GmbH (Germany)

Willach GmbH (Germany)

……..

This competitive era requires companies to be equipped with the know-how of major market events and pharmaceutical automation industry. The Pharmaceutical Automation Industry market report has been structured after an in-depth study of various key market segments such as market size, share, growth, demand, latest trends, market threats, and key drivers driving the market. Market segmentation is done in terms of markets covered, geographical scope, years considered for the study, currency and price, research methodology, primary interviews with key opinion leaders, DBMR Market Position Matrix, DBMR Market Challenges Matrix, Secondary Sources and Assumptions. For better decisions, more revenue generation and profitable business, such a market research report on Pharmacy Automation industry is the key. All this data and information is very important for companies when it comes to characterizing production, marketing, sales, promotion and distribution strategies for products and services.

Pharmacy Automation Market Dynamics

Drivers

Increased demand to minimize medication errors

Medication and dispensing errors are widely recognized as the leading causes of hospital readmissions worldwide. Medication error can occur due to a number of factors, including poor communication between doctor and pharmacist, unsafe pharmacy storage practices, and confusion caused by using similar labels, which will expedite market growth.

Technological development

Introduction of technological advancements and development of automated systems with improved pharmacy automation systems results in higher success rate and new applications of the device with higher demand for innovative products to compose, dispense, store and label prescription drugs, propelling the growth of the pharmacy automation market.

Increase in the geriatric population

There has been an increase in the global geriatric population. As a result, the prevalence of chronic and life-threatening diseases is increasing just as the distribution of drugs is further expected to propel the growth of the market.

Opportunities

Furthermore, the growing awareness among pharmacists is further expected to offer potential opportunities for the growth of the pharmacy automation market in the coming years.

Constraints/Challenges

On the other hand, the lack of adoption of pharmacy automation systems is further expected to hamper the growth of the pharmacy automation market over the targeted period. However, the stringent regulatory procedures might still challenge the growth of the pharmacy automation market in the near future.

Global pharmacy automation market scope and market size

Product

  • Systems
  • Software
  • Services

Type of pharmacy

  • Independent
  • Chain
  • Federal

Pharmacy size

  • Large pharmacy
  • Medium-sized pharmacy
  • Small pharmacy

Application

  • Distribution and packaging of drugs
  • Medication storage
  • Inventory management

Final user

  • Inpatient pharmacies
  • Ambulatory pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Central Filling/Mail Order Pharmacies
  • Pharmacy benefit management organizations
  • Others

Distribution channel

  • Direct call for tenders
  • Third Party Distributor

Research methodology :

  • Both top-down and bottom-up approaches are used to estimate and validate the global Pharmacy Automation market size
  • In order to attain an exhaustive list of functional and relevant players who offer pharmacy automation, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies .
  • Subsequently, a thorough validation test is carried out to reach the most relevant players having a specific product line, i.e. Pharmacy Automation.
  • In order to make the list prioritized, sorting is done based on revenue generation according to the latest reports using paid databases such as Factiva, Bloomberg, etc.
  • Finally, the questionnaire is defined and specifically designed to meet all the necessities of primary data collection after obtaining a prior appointment. This helps us gather data on revenue, profit, revenue, growth, etc. players.
  • Nearly 80% of data is collected through primary medium and further validation is done through various secondary sources including regulators, World Bank, association, company website, annual reports, press releases press, etc

The full report is available (including full table of contents, list of tables and figures, charts and graph) @ https://www.databridgemarketresearch.com/toc/?dbmr=global-pharmacy-automation-market&Ab

Some of the important questions for stakeholders and business professionals to expand their position in the pharmacy automation market:

Q 1. Which Region offers the most rewarding open doors for the market before 2022?

Q 2. What are the trade threats and impact of latest scenario on market growth and estimation?

Q 3. What are probably the most encouraging development scenarios for the Pharmacy Automation movement showcase by applications, types and regions?

Q 4.Which segments are attracting the most attention in the pharmacy automation market in 2022 and beyond?

Q 5. Who are the significant players competing and growing in the Pharmacy Automation Market?

Thank you for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

]]>
Pharmacy alumnus and husband donate $6 million to name Purdue’s first-ever dean https://pricesvardenafillevitra.com/pharmacy-alumnus-and-husband-donate-6-million-to-name-purdues-first-ever-dean/ Fri, 10 Jun 2022 19:52:55 +0000 https://pricesvardenafillevitra.com/pharmacy-alumnus-and-husband-donate-6-million-to-name-purdues-first-ever-dean/ WEST LAFAYETTE, Ind. – Purdue College of Pharmacy’s most generous donors have made history by funding the university’s first-ever dean. Jeannie (Bachelor of Science, Pharmacy, 1961) and Jim Chaney pledged $6 million to benefit the College of Pharmacy. Beginning July 1, their gift will establish the Jeannie and Jim Chaney Dean of Pharmacy for the […]]]>

WEST LAFAYETTE, Ind. – Purdue College of Pharmacy’s most generous donors have made history by funding the university’s first-ever dean.

Jeannie (Bachelor of Science, Pharmacy, 1961) and Jim Chaney pledged $6 million to benefit the College of Pharmacy. Beginning July 1, their gift will establish the Jeannie and Jim Chaney Dean of Pharmacy for the next five years as well as the Jeannie and Jim Chaney Dean of Pharmacy Excellence Fund Endowment. At the end of the initial term, donors will have the option of extending, renewing, pivoting, or making their appointed deanship permanent.

Together, these gifts immediately elevate the prestige of the college while enabling the Dean to make strategic investments in emerging priority areas and launch new initiatives that impact faculty, staff, and students. Given on the record-breaking Purdue Day of Giving, Chaney’s donation led the College of Pharmacy to the top of the donation charts with a total of $8,231,980 raised during the effort in April.

“We see a need for Purdue pharmacy students to have the best education they can get while they’re in school,” Jeannie Chaney said. “There is a huge need for pharmacists right now, and to meet that need, people have to step up. Dean Barker has a vision of where the college needs to go in the years to come – he knows what is needed. We saw this play out as he led the Protect Purdue committee to toe the narrow line of keeping students safe while pursuing their education.

Jim Chaney said: “Dean Barker has been a tremendous leader for the College of Pharmacy, and we have wanted to invest in his vision for some time. Our relationship with the college has made a significant difference for us, and our financial commitments have grown exponentially as our relationship has evolved. We are delighted to see the positive impact of our donations over many years.

Jeannie Chaney was a pharmacist in Ohio for nearly 50 years before retiring in 2011. She served as Chair of the President’s Council and a member of the Pharmacy Women for Purdue Steering Committee and the Pharmacy Alumni Board. Jim Chaney is president of Cleveland Syrup Co., which supplies sweeteners to food manufacturing companies. He earned his bachelor’s degree in economics from Denison University.

Flexibility and creativity have been hallmarks of the Chaneys’ gift to Purdue. In 2018, the couple donated an additional $8 million to their Pacesetter Endowment for Pharmacy, which now offers scholarships and will ultimately support the nursing and pharmacy education building project. This dual-purpose endowment appealed to the Chaneys because their investment created impact from the start. Similarly, the Chaneys’ 2022 commitment has the flexibility to meet the college’s greatest current need—strategic investment funds for the dean—with the ability to rotate as the college’s needs or interests change. long-term donors are changing.

“Having these types of discretionary funds allows us to make priority investments in real time, such as our Emerging Leaders program as well as health equity, drug discovery and pharmaceutical manufacturing efforts,” said Eric Barker, Dean from the College of Pharmacy. “Jeannie and Jim have once again shown extraordinary generosity. This latest gift reflects their deep friendship with the college and their commitment to making Purdue’s College of Pharmacy the best in the country.

The Chaneys have supported a wide range of strategic opportunities at Purdue, including a principal gift for the Chaney-Hale Hall of Science, which opened in 2020, and a variety of funds and awards in support of students and scholars. teachers. Overall, the Chaney family has supported the college and university for 44 years with a combined total of nearly $25.5 million in philanthropic support.

“Jim and Jeannie are role models of philanthropy and generosity who love Purdue and understand how to impact strategic change through their donations,” Purdue Chairman Mitch Daniels said. “Their donations elevate all of Purdue as they continue to invest in our students and faculty. We are forever grateful for their vision for our Faculty of Pharmacy and beyond.

About Purdue University

Purdue University is a leading public research institution that develops practical solutions to today’s toughest challenges. Ranked in each of the past four years as one of the 10 most innovative universities in the United States by US News & World Report, Purdue delivers groundbreaking research and groundbreaking discoveries. Committed to hands-on, online, real-world learning, Purdue provides transformative education for all. Committed to affordability and accessibility, Purdue has frozen tuition and most fees at 2012-13 levels, allowing more students than ever to graduate debt-free. Find out how Purdue never stops in the persistent pursuit of the next giant leap at https://stories.purdue.edu.

Writer: Katie Donworth, kedonworth@purdueforlife.org

Media contact: Jim Bush, jsbush@purdue.edu

]]>